Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK1 R629_S632delinsSA |
Therapy | Tofacitinib |
Indication/Tumor Type | hypereosinophilic syndrome |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK1 R629_S632delinsSA | hypereosinophilic syndrome | predicted - sensitive | Tofacitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib) treatment resulted in decreased viability of blood and marrow cells derived from a patient with hypereosinophilia harboring JAK1 R629_S632delinsSA in culture (PMID: 34496019). | 34496019 |
PubMed Id | Reference Title | Details |
---|---|---|
(34496019) | A novel activating JAK1 mutation in chronic eosinophilic leukemia. | Full reference... |